





**Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax**

Hockings et al.



**Supplementary Figure 1. A C-terminal HA tag does not alter Bid function.**

Wild type MLM were incubated with two forms of Bid as indicated, and assessed for cytochrome *c* release and for Bak conformation change by susceptibility to proteinase K (PK)(Ma et al, *Cell Death Differ* 2014; 21: 1925-1935). Note that thrombin-cleaved Bid-HA and caspase-8-cleaved Bid activated Bak (convert to a PK-sensitive conformation) and induced cytochrome *c* release with the same potency. Blots are representative of two independent experiments.


**a****b****c**

**Supplementary Figure 2. Bim, Noxa, Bmf and Bak BH3 domains contain a residue that may destabilize the Bid chimera.**

(a) Sequence alignment of the BH3 peptides used in this study, highlighting the h0-h4 positions in the BH3 domain. The presence of glutamate or methionine at the equivalent Bid I83 position is highlighted (red). Note that when generated as 20-residue swaps in Bid, the resulting four Bid chimeras (Bid<sup>Bim</sup>, Bid<sup>Noxa</sup>, Bid<sup>Bmf</sup> and Bid<sup>Bak</sup>) were unstable (not shown).

(b) Bid I83 contacts hydrophobic residues in helices 1, 3 and 8. Cartoon representation of human Bid (Chou et al, *Cell* 1999; 96: 615-624) with sidechains shown for I83 and contacting hydrophobic residues.

(c) Bid chimeras efficiently target membranes. The indicated Bid chimeras (5 nM, diluted in 1% BSA) were incubated with *Bak*<sup>-/-</sup> MLM for 1 h at 37 °C. Supernatant (sup) and pellet (pel) fractions were Western blotted for HA (HA-tagged chimeras). Blots are representative of two independent experiments.




### Supplementary Figure 3. Bid chimeras bind to the canonical hydrophobic groove in full-length Bcl-x<sub>L</sub>.

(a) Quantitation of Bid chimera binding to prosurvival proteins (related to Figure 2). Co-immunoprecipitation of chimeras with the indicated prosurvival proteins is shown for three separate experiments including those in Figure 2 (*upper blots*). Upper bar charts show the co-IP of each chimera (mean and SEM for the top two blots) relative to the strongest band on each blot. While the lower blots reflect the same pattern of co-IP, they were not included in the bar chart data due to overexposed bands (\*) or missing sample (X). Lower bar charts show peptide binding affinities measured by SPR as in Figure 2.

(b) The BH3 mimetic ABT-737 prevents Bid chimeras binding to Bcl-x<sub>L</sub>. Bid, Bid<sup>Bim</sup> and Bid<sup>Bik</sup> (40 nM, diluted in 1% BSA) were incubated with full-length hBcl-x<sub>L</sub> (40 nM) and *Bak*<sup>-/-</sup> MLM, in the presence or absence of ABT-737 (10 μM). Samples were immunoprecipitated (IP) for Bcl-x<sub>L</sub> as in Figure 2 and Western blotted (WB) for HA (HA-tagged chimeras) or Bcl-x<sub>L</sub>.


(c) Full-length Bcl-x<sub>L</sub> associates with the membrane fraction while truncated Bcl-x<sub>L</sub> remains largely in the supernatant. Bcl-x<sub>L</sub> or Bcl-x<sub>L</sub>ΔC (40 nM, diluted in 1% BSA) were incubated with *Bak*<sup>-/-</sup> MLM for 2 h at 37 °C and separated into supernatant (sup) and pellet (pel) and Western blotted (WB) for Bcl-x<sub>L</sub>.

Blots for (b) and (c) are representative of at least two independent experiments.



**Supplementary Figure 4. Chimeras and peptides show no apparent preference for activating Bak versus Bax.**

EC<sub>50</sub> values from Figure 3b were plotted to compare the ability of each chimera or peptide to activate Bak (*x*-axis) and Bax (*y*-axis), with corresponding error bars (SEM) shown. Correlation was calculated using Prism 6 (Graphpad) from logarithms of EC<sub>50</sub> values on a linear scale, and a logarithmic scale applied for ease of reading.  $r^2 = 0.76$  for chimeras and  $r^2 = 0.74$  for peptides.



**Supplementary Figure 5. Bid<sup>Bad</sup> and Bad BH3 peptide initiated cytochrome c release is often incomplete.**

Repeat experiments for MLM cytochrome *c* release by the Bid<sup>Bad</sup> chimera and Bad BH3 peptide are shown, as well as the Bid and Bid<sup>Bik</sup> data from Figure 3b. The Bid<sup>Bad</sup> chimera and Bad BH3 data from Figure 4 are the traces with open circles. Note that release initiated by Bid and Bid<sup>Bik</sup> becomes complete when concentration is increased 3- to 10-fold, whereas release initiated by Bid<sup>Bad</sup> and Bad peptide is more graded and often incomplete.